An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Teriparatide (Primary) ; Parathyroid hormone
- Indications Hypoparathyroidism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Entera Bio
- 23 Sep 2019 According to an Entera Bio media release, full data from this study will be published in a leading medical journal.
- 23 Sep 2019 According to an Entera Bio media release, Professor Sofia Ish-Shalom, at the Endocrine Research Center at Lin Medical Center, is the principal investigator of this study.
- 23 Sep 2019 According to an Entera Bio media release, data (n=16) from this study were presented at the merican Society for Bone and Mineral Research (ASBMR) Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History